当前位置: 首页 >> 检索结果
7863. "The Secret Life of Human Donor Hearts": An Examination of Transcriptomic Events During Cold Storage.
作者: Ienglam Lei.;Zhong Wang.;Y Eugene Chen.;Peter X Ma.;Wei Huang.;Elaine Kim.;Hugo Y K Lam.;Daniel R Goldstein.;Keith D Aaronson.;Francis D Pagani.;Paul C Tang.
来源: Circ Heart Fail. 2020年13卷4期e006409页
Ischemic tolerance of donor hearts has a major impact on the efficiency in utilization and clinical outcomes. Molecular events during storage may influence the severity of ischemic injury.
7864. Safety, Performance, and Efficacy of Cardiac Contractility Modulation Delivered by the 2-Lead Optimizer Smart System: The FIX-HF-5C2 Study.
作者: Phi Wiegn.;Rodrigo Chan.;Charles Jost.;Benjamin R Saville.;Helen Parise.;David Prutchi.;Peter E Carson.;Angela Stagg.;Rochelle L Goldsmith.;Daniel Burkhoff.
来源: Circ Heart Fail. 2020年13卷4期e006512页
Prior studies of cardiac contractility modulation (CCM) employed a 3-lead Optimizer system. A new 2-lead system eliminated the need for an atrial lead. This study tested the safety and effectiveness of this 2-lead system compared with the 3-lead system.
7865. Clinical Outcomes and Quality of Life With an Ambulatory Counterpulsation Pump in Advanced Heart Failure Patients: Results of the Multicenter Feasibility Trial.
作者: Nir Uriel.;Valluvan Jeevanandam.;Teruhiko Imamura.;David Onsager.;Tae Song.;Takeyoshi Ota.;Colleen Juricek.;Pamela Combs.;Thomas Lammy.;Sonna Patel-Raman.;Joshua R Woolley.;Gabriel Sayer.;Carmelo Milano.;Jacob Schroder.;Ezequiel Molina.;Jonathan Grinstein.;Erik Suarez.;Jerry D Estep.;Sanjeev Aggarwal.;Scott Silvestry.;Nirav Raval.; .
来源: Circ Heart Fail. 2020年13卷4期e006666页
The NuPulseCV intravascular ventricular assist system (iVAS) provides extended duration ambulatory counterpulsation via a durable pump placed through the distal subclavian artery.
7866. Factor Xa Inhibitor-Related Intracranial Hemorrhage: Results From a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates.
作者: Nicholas G Panos.;Aaron M Cook.;Sayona John.;G Morgan Jones.; .
来源: Circulation. 2020年141卷21期1681-1689页
Since the approval of the oral factor Xa inhibitors, there have been concerns regarding the ability to neutralize their anticoagulant effects after intracranial hemorrhage (ICH). Multiple guidelines suggest using prothrombin complex concentrates (PCCs) in these patients on the basis of research that includes a limited number of patients with ICH. Given this, we aimed to evaluate the safety and efficacy of PCCs for factor Xa inhibitor-related ICH in a large, multicenter cohort of patients.
7867. Cardiac Overexpression of PDE4B Blunts β-Adrenergic Response and Maladaptive Remodeling in Heart Failure.
作者: Sarah Karam.;Jean Piero Margaria.;Aurélia Bourcier.;Delphine Mika.;Audrey Varin.;Ibrahim Bedioune.;Marta Lindner.;Kaouter Bouadjel.;Matthieu Dessillons.;Françoise Gaudin.;Florence Lefebvre.;Philippe Mateo.;Patrick Lechène.;Susana Gomez.;Valérie Domergue.;Pauline Robert.;Charlène Coquard.;Vincent Algalarrondo.;Jane-Lise Samuel.;Jean-Baptiste Michel.;Flavien Charpentier.;Alessandra Ghigo.;Emilio Hirsch.;Rodolphe Fischmeister.;Jérôme Leroy.;Grégoire Vandecasteele.
来源: Circulation. 2020年142卷2期161-174页
The cyclic AMP (adenosine monophosphate; cAMP)-hydrolyzing protein PDE4B (phosphodiesterase 4B) is a key negative regulator of cardiac β-adrenergic receptor stimulation. PDE4B deficiency leads to abnormal Ca2+ handling and PDE4B is decreased in pressure overload hypertrophy, suggesting that increasing PDE4B in the heart is beneficial in heart failure.
7868. Code Blue During the COVID-19 Pandemic.
作者: Paul S Chan.;Robert A Berg.;Vinay M Nadkarni.
来源: Circ Cardiovasc Qual Outcomes. 2020年13卷5期e006779页
The surging COVID-19 pandemic has raised ethical and moral dilemmas that Western nations with first-rate medical care facilities rarely confront—how to best allocate standard life-saving medical resources when escalating demand outstrips supply. Sadly, these quandaries are familiar challenges in resource-poor countries. What makes this pandemic notable is that the scope and number of reported cases have been primarily in First World nations, raising questions in some settings about the use of emergency treatments like resuscitation care for in-hospital cardiac arrest (IHCA). This perspective reviews the debate around these ethical and moral dilemmas more broadly but focuses specifically on IHCA and the response of the medical community.
7873. Fetal Aortic Valvuloplasty for Evolving Hypoplastic Left Heart Syndrome: A Decision Analysis.
作者: Sarah S Pickard.;John B Wong.;Emily M Bucholz.;Jane W Newburger.;Wayne Tworetzky.;Terra Lafranchi.;Carol B Benson.;Louise E Wilkins-Haug.;Diego Porras.;Ryan Callahan.;Kevin G Friedman.
来源: Circ Cardiovasc Qual Outcomes. 2020年13卷4期e006127页
Fetal aortic valvuloplasty (FAV) may prevent progression of midgestation aortic stenosis to hypoplastic left heart syndrome. However, FAV has well-established risks, and its survival benefit remains unknown. Our primary aim was to determine whether FAV for midgestation aortic stenosis increases survival from fetal diagnosis to age 6 years.
7874. Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial.
作者: Natalia C Berry.;Laura Mauri.;Philippe Gabriel Steg.;Deepak L Bhatt.;Stefan H Hohnloser.;Matias Nordaby.;Corinna Miede.;Takeshi Kimura.;Gregory Y H Lip.;Jonas Oldgren.;Jurriën M Ten Berg.;Christopher P Cannon.
来源: Circ Cardiovasc Interv. 2020年13卷4期e008349页
The REDUAL PCI trial (Evaluation of Dual Therapy With Dabigatran vs Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting) demonstrated that, in patients with atrial fibrillation following percutaneous coronary intervention, bleeding risk was lower with dabigatran plus clopidogrel or ticagrelor (dual therapy) than warfarin plus clopidogrel or ticagrelor and aspirin (triple therapy). Dual therapy was noninferior for risk of thromboembolic events. Whether these results apply equally to patients at higher risk of ischemic events due to lesion complexity or clinical risk factors is unclear.
7876. Association of Parkinson Disease With Risk of Cardiovascular Disease and All-Cause Mortality: A Nationwide, Population-Based Cohort Study.
作者: Joo-Hyun Park.;Do-Hoon Kim.;Yong-Gyu Park.;Do-Young Kwon.;Moonyoung Choi.;Jin-Hyung Jung.;Kyungdo Han.
来源: Circulation. 2020年141卷14期1205-1207页 7877. Response by Park and Park to Letter Regarding Article, "Clinically Significant Bleeding With Ticagrelor Versus Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management: A Randomized Clinical Trial".7880. Letter by Chen et al Regarding Article, "Clinically Significant Bleeding With Ticagrelor Versus Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management: A Randomized Clinical Trial". |